Technology evaluation: CN-706, Calydon Inc.
CN-706, an engineered adenovirus containing the prostate tissue-specific enhancer (PSE) gene is under development by Calydon as a potential treatment for prostate cancer. The company is collaborating with the Johns Hopkins Hospital, which has agreed to sponsor clinical trials [274956]. Phase I trials in patients with advanced and recurring prostate cancer began during 1998 at the Johns Hopkins Brady Urological Institute and the Oncology Center [283946], [296857], and the results of phase I/II trials were reported in 2000 [386879]. The US Patent Office issued three patents in October 1998 [301251] related to Calydon's technology for engineering viruses to replicate and kill prostate cancer cells [US-05648478], [US-05698443], [US-05783435]. In June 1999, Calydon was issued two further patents [US-05871726], [US-05830686], [327511].